UMIN-CTR Clinical Trial

Recruitment status Preinitiation
Unique ID issued by UMIN UMIN000039447
Receipt No. R000044978
Scientific Title Study on the depiction of skeletal muscle function of sarcopenia using diffusion tensor imaging
Date of disclosure of the study information 2020/03/01
Last modified on 2020/02/10 (Ver. 1)

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information
Public title Evaluation of the skeletal muscle function using diffusion tensor imaging
Acronym Evaluation of the skeletal muscle using diffusion tensor imaging
Scientific Title Study on the depiction of skeletal muscle function of sarcopenia using diffusion tensor imaging
Scientific Title:Acronym Evaluation of the skeletal muscle using diffusion tensor imaging
Region
Japan

Condition
Condition sarcopenia
Classification by specialty
Orthopedics Rehabilitation medicine
Classification by malignancy Others
Genomic information NO

Objectives
Narrative objectives1 To establish morphological and functional evaluation of skeletal muscle using diffusion tensor imaging
Basic objectives2 Efficacy
Basic objectives -Others
Trial characteristics_1
Trial characteristics_2
Developmental phase

Assessment
Primary outcomes The diffusion tensor imaging parameter of skeletal muscle
Key secondary outcomes SARC-F (Questionnaire)
Lower leg circumference
Grip power
Lower limb muscle strength
Physical ability (walking speed,timed-up-and-go test (TUG) , Chair rise test)
Balance ability (Functional reach test, Standing on single leg)
Body composition

Base
Study type Interventional

Study design
Basic design Parallel
Randomization Non-randomized
Randomization unit
Blinding Open -no one is blinded
Control No treatment
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment

Intervention
No. of arms 2
Purpose of intervention Diagnosis
Type of intervention
Other
Interventions/Control_1 Evaluation of physical function and body composition, and MRI imaging are performed for the sarcopenia group.
Interventions/Control_2 Evaluation of physical function and body composition, and MRI imaging are performed for the non-sarcopenia group.
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10

Eligibility
Age-lower limit
65 years-old <=
Age-upper limit

Not applicable
Gender Male and Female
Key inclusion criteria 1.Patients in hospital or outpatient of hospital of Kyoto Prefectural University of Medicine, or a person who participated in the Uzumasa physical fitness measurement at Kyoto University of Advanced Science
2.Patients who consent to study participation with the document by free will
3.Patients aged 65 and over at the time of consent acquisition
4.Gender does not matter

[Sarcopenia group:10 people]
1) The lower leg circumference is below the sarcopenia screening standard value by AWGS (Asian Working Group for Sarcopenia) 2019
cut-off value: male<34cm, female<33cm
2)Those who meet the sarcopenia diagnostic criteria by AWGS 2019 (sarcopenia, severe sarcopenia; A+B, A+C, or A+B+C)
A. Low skeletal muscle mass evaluated by Bioelectrical Impedance Analysis
cut-off value:male<7.0kg/m2, female<5.7kg/m2
B. Low muscle strength evaluated by grip power
cut-off value:male<28kg, female<18kg
C. Low physical function evaluated by walking speed
cut-off value<1.0m/s

[Non-sarcopenia group:10 people]
Those who do not meet the above criteria
Key exclusion criteria 1. Pregnant woman
2. Inappropriate MRI imaging
for the following reasons
Pacemaker user
History of cerebral artery clipping
Use non-MRI compatiblemetal implants in the body
Use of metal implant in lower leg
Tattoo and art makeup
Claustrophobia
3. Those who have difficulty assessing motor function for the following reasons
History of myocardial infarction,
symptomatic angina or arrhythmias.
Uncontrolled tachycardia
Uncontrolled hypertension
Symptomatic lung disease
High risk of fracture
Infectious disese
4. Others. The person whom the doctor judged inappropriate
Target sample size 20

Research contact person
Name of lead principal investigator
1st name Suzuyo
Middle name
Last name Ohashi
Organization Graduate School of Medical Science, Kyoto Prefectural University of Medicine
Division name Department of Rehabilitation Medicine
Zip code 602-8566
Address 465, Kawaramachi-Hirokoji, Kamigyo-ku, Kyoto
TEL 075-251-5324
Email reha@koto.kpu-m.ac.jp

Public contact
Name of contact person
1st name Suzuyo
Middle name
Last name 0hashi
Organization Graduate School of Medical Science, Kyoto Prefectural University of Medicine
Division name Department of Rehabilitation Medicine
Zip code 602-8566
Address 465, Kawaramachi-Hirokoji, Kamigyo-ku, Kyoto
TEL 075-251-5324
Homepage URL
Email reha@koto.kpu-m.ac.jp

Sponsor
Institute Department of Rehabilitation Medicine, Graduate School of Medical Science, Kyoto Prefectural University of Medicine
Institute
Department

Funding Source
Organization Japan society for the promotion of science
Organization
Division
Category of Funding Organization Japanese Governmental office
Nationality of Funding Organization

Other related organizations
Co-sponsor
Name of secondary funder(s)

IRB Contact (For public release)
Organization Kyoto Prefectural University of Medicine, Clinical Research Review Board
Address 465, Kawaramachi-Hirokoji, Kamigyo-ku, Kyoto, 602-8566, Japan
Tel 075-251-5111
Email rinri@koto.kpu-m.ac.jp

Secondary IDs
Secondary IDs NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW

Institutions
Institutions

Other administrative information
Date of disclosure of the study information
2020 Year 03 Month 01 Day

Related information
URL releasing protocol
Publication of results Unpublished

Result
URL related to results and publications
Number of participants that the trial has enrolled
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description

Progress
Recruitment status Preinitiation
Date of protocol fixation
2020 Year 02 Month 10 Day
Date of IRB
Anticipated trial start date
2020 Year 04 Month 01 Day
Last follow-up date
2023 Year 03 Month 31 Day
Date of closure to data entry
Date trial data considered complete
Date analysis concluded

Other
Other related information

Management information
Registered date
2020 Year 02 Month 10 Day
Last modified on
2020 Year 02 Month 10 Day


Link to view the page
URL(English) https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000044978